-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Caris Life Sciences, Lowers Price Target to $28

Benzinga·05/08/2026 20:22:56
Listen to the news
Citigroup analyst Patrick Donnelly maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the price target from $35 to $28.